Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or have received and progressed on a docetaxel containing regimen,
Prostate Cancer
DRUG: AT-101
Safety of AT-101 in combination with docetaxel and prednisone, 12 months
Preliminary efficacy of AT-101 in combination with docetaxel and prednisone, 12 months
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or have received and progressed on a docetaxel containing regimen,